Abstract:
The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.
Abstract:
The invention relates to 5-thiapethilones and 15-disubstituted epothilones according to formula I (I) with the following meanings: X= >C = O or >S = O R 1 = C 1-6 alkyl or C 2-6 alkenyl R 2 = H or C 1-6 alkyl Y - Z = >C=C C- O -C 3 = H, C 1-6 alkyl or C 2-6 alkenyl R 4 = bicycloaryl, bicycloheteroaryl or -C(R 5 ) = CH-R 6 , where R 5 = H or CH 3 and R 6 = aryl or heteroaryl X not being >C=O if R 3 = H.
Abstract translation:本发明涉及式I(I)的5-硫代二甲苯酮和15-二取代的埃博霉素,其含义如下:X => C = O或> S = OR 1 = C 1-6烷基或C 2-6烯基R' 2> = H或C 1-6烷基Y -Z = C = C OR OR CO(环氧化物环)R 3 = H,C 1-6烷基或C 2-6烯基R 4 =双环芳基,双环杂芳基 或-C(R 5)= CH-R 6,其中R 5 = H或CH 3且R 6 =芳基或杂芳基X,如果R 3 = H,则不为> C = O。
Abstract:
The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
Abstract:
The present invention provides a process for preparing thiazole derivatives of formula (XI), that activate the delta subtype of the human Peroxisome Proliferator Activated Receptor (hPPARδ), and also provides processes for compounds of formula (VI), (VII), (VIII) and (IX), intermediate compounds for preparation of the above compounds of formula (XI).
Abstract:
This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
Abstract:
This invention relates to novel compounds characterized by the general Formula (I) any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, or an N-oxide thereof, useful as potassium channel modulators. More specifically the invention provides chemical compounds useful as modulators of SK Ca and/or IK Ca channels.
Abstract:
The present invention provides compounds of Formula (I): f I wherein A, X, Q, Y, B, D, Z, and E have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, process for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.
Abstract:
The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making
Abstract:
The present application is directed to chemical compounds of formula (I-A) or formula (II-A) (in which the variables are as defined in the claims), compositions containing them and uses of the compositions for treating sleepiness, tiredness Parkinson's disease, cerebral ischaemia, stroke, sleep apneas, eating disorders, attention deficit hyperactivity disorder, cognitive dysfunction or fatigue, for the promotion of wakefulness, stimulation of appetite or weight gain or for the treatment of disorders associated with hypofunctionality of the cerebral cortex such as depression, schizophrenia and chronic fatigue syndrome.
Abstract:
Compounds of the general formula (I), their optical isomers or prodrugs, pharmaceutically acceptable salts of the compounds, the isomers, or the prodrugs, or solvates of the same; and metalloprotease inhibitors containing the compounds, the optical isomers, the prodrugs, the salts, or the solvates: (I) wherein R is hydroxyl or the like; R is optionally substituted lower alkyl or the like; R is hydrogen or the like; R is optionally substituted arylene or the like; R is a group of formula (II) or (III): (III) and R is optionally substituted aryl or the like.
Abstract translation:通式(I)的化合物,它们的光学异构体或前体药物,化合物的药学上可接受的盐,异构体或前药或其溶剂合物; 和含有这些化合物的金属蛋白酶抑制剂,光学异构体,前体药物,盐或溶剂合物:(I)其中R 1是羟基等; R 2是任选取代的低级烷基等; R 3是氢等; R 4是任选取代的亚芳基等; R 5是式(II)或(III)的基团:(III),R 6是任选取代的芳基等。